JP7769650B2 - 抗がん薬としてのキノキサリン誘導体 - Google Patents

抗がん薬としてのキノキサリン誘導体

Info

Publication number
JP7769650B2
JP7769650B2 JP2022579869A JP2022579869A JP7769650B2 JP 7769650 B2 JP7769650 B2 JP 7769650B2 JP 2022579869 A JP2022579869 A JP 2022579869A JP 2022579869 A JP2022579869 A JP 2022579869A JP 7769650 B2 JP7769650 B2 JP 7769650B2
Authority
JP
Japan
Prior art keywords
methyl
fluoro
quinoxalin
piperazin
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022579869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532257A (ja
JP2023532257A5 (cg-RX-API-DMAC7.html
Inventor
ジョン パッカー,マーティン
ルイ ドゥゴース,セバスチャン
ウォレス ジョハネス,ジェフリー
マハデオ ハンデ,スディール
ゴーシュ,アビプサ
ジェン,シャオラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023532257A publication Critical patent/JP2023532257A/ja
Publication of JP2023532257A5 publication Critical patent/JP2023532257A5/ja
Application granted granted Critical
Publication of JP7769650B2 publication Critical patent/JP7769650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022579869A 2020-06-25 2021-06-24 抗がん薬としてのキノキサリン誘導体 Active JP7769650B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063044095P 2020-06-25 2020-06-25
US63/044,095 2020-06-25
US202063120351P 2020-12-02 2020-12-02
US63/120,351 2020-12-02
PCT/EP2021/067304 WO2021260092A1 (en) 2020-06-25 2021-06-24 Quinoxaline derivatives as anti-cancer drugs

Publications (3)

Publication Number Publication Date
JP2023532257A JP2023532257A (ja) 2023-07-27
JP2023532257A5 JP2023532257A5 (cg-RX-API-DMAC7.html) 2024-06-19
JP7769650B2 true JP7769650B2 (ja) 2025-11-13

Family

ID=76662494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579869A Active JP7769650B2 (ja) 2020-06-25 2021-06-24 抗がん薬としてのキノキサリン誘導体

Country Status (22)

Country Link
US (3) US11795158B2 (cg-RX-API-DMAC7.html)
EP (1) EP4172152A1 (cg-RX-API-DMAC7.html)
JP (1) JP7769650B2 (cg-RX-API-DMAC7.html)
KR (1) KR102980562B1 (cg-RX-API-DMAC7.html)
CN (7) CN122059929A (cg-RX-API-DMAC7.html)
AU (1) AU2021295423B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025435A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186996A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003711A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000186A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230024A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000288A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005059A (cg-RX-API-DMAC7.html)
IL (1) IL299123B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022015435A (cg-RX-API-DMAC7.html)
PE (1) PE20231081A1 (cg-RX-API-DMAC7.html)
SA (1) SA522441701B1 (cg-RX-API-DMAC7.html)
TW (1) TWI925847B (cg-RX-API-DMAC7.html)
UA (1) UA130043C2 (cg-RX-API-DMAC7.html)
UY (1) UY39296A (cg-RX-API-DMAC7.html)
WO (1) WO2021260092A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300924B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer
TW202309025A (zh) 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
AU2022280845A1 (en) 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
JP2024522736A (ja) * 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
WO2023051807A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CA3238572A1 (en) 2021-11-19 2023-05-25 Jing Zhang Selective parp1 inhibitor and application thereof
AU2022422276B2 (en) * 2021-12-21 2025-12-11 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CA3246093A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. PARP1 INHIBITORS AND THEIR USES
AU2023212785A1 (en) * 2022-01-28 2024-08-15 Xinthera, Inc. Parp1 inhibitors and uses thereof
CN116693501B (zh) * 2022-02-10 2025-12-19 康百达(四川)生物医药科技有限公司 一种喹唑啉酮衍生物及其在医药上的应用
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
PT4497438T (pt) * 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
AU2023275808A1 (en) 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
US20250346573A1 (en) * 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
KR20250023494A (ko) 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
US20240174669A1 (en) * 2022-10-06 2024-05-30 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
KR20250103773A (ko) 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
CR20250267A (es) 2022-12-06 2026-01-14 Astrazeneca Ab Inhibidores de polq
WO2024255782A1 (zh) 2023-06-14 2024-12-19 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
WO2025067417A1 (zh) 2023-09-28 2025-04-03 成都赜灵生物医药科技有限公司 并内酰胺环类化合物及其用途
WO2025092973A1 (zh) * 2023-11-03 2025-05-08 成都赜灵生物医药科技有限公司 Parp1靶向化合物及其用途
AU2024394093A1 (en) 2023-12-05 2026-06-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
CN120398887A (zh) * 2024-01-31 2025-08-01 西藏海思科制药有限公司 一种双环衍生物parp抑制剂的晶型及其制备方法和应用
KR20250128449A (ko) 2024-02-20 2025-08-28 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
WO2025248119A1 (en) 2024-05-31 2025-12-04 Astrazeneca Ab 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors
TW202608880A (zh) 2024-05-31 2026-03-01 瑞典商阿斯特捷利康公司 Polq抑制劑
KR20260019426A (ko) 2024-08-01 2026-02-10 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
GB2703160A (en) * 2024-12-09 2026-07-15 Duke Street Bio Ltd PARP1 Inhibitor Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500758A (ja) 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキノリノン誘導体
JP2012515786A (ja) 2009-01-23 2012-07-12 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
JP2018521033A (ja) 2015-06-09 2018-08-02 ジェ イル ファーマシューティカル カンパニー リミテッド 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
JP2009196973A (ja) * 2007-09-26 2009-09-03 Santen Pharmaceut Co Ltd キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
WO2014045101A1 (en) * 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
HK1211033A1 (en) * 2012-12-20 2016-05-13 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500758A (ja) 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキノリノン誘導体
JP2012515786A (ja) 2009-01-23 2012-07-12 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
JP2018521033A (ja) 2015-06-09 2018-08-02 ジェ イル ファーマシューティカル カンパニー リミテッド 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物

Also Published As

Publication number Publication date
BR112022025435A2 (pt) 2023-01-24
SA522441701B1 (ar) 2024-08-11
IL299123B1 (en) 2025-12-01
AU2021295423B2 (en) 2024-05-02
US20220009901A1 (en) 2022-01-13
KR102980562B1 (ko) 2026-06-23
US11795158B2 (en) 2023-10-24
CN122036687A (zh) 2026-05-15
AU2021295423A1 (en) 2023-02-16
PE20231081A1 (es) 2023-07-17
CR20230024A (es) 2023-03-01
CN122036686A (zh) 2026-05-15
CN121949283A (zh) 2026-05-01
US12421208B2 (en) 2025-09-23
JP2023532257A (ja) 2023-07-27
TW202218664A (zh) 2022-05-16
CN122010903A (zh) 2026-05-12
CN115768760A (zh) 2023-03-07
IL299123A (en) 2023-02-01
IL299123B2 (en) 2026-04-01
UA130043C2 (uk) 2025-10-22
CL2022003711A1 (es) 2023-06-23
DOP2022000288A (es) 2023-01-15
CN115768760B (zh) 2026-03-27
UY39296A (es) 2021-12-31
EP4172152A1 (en) 2023-05-03
ECSP23005059A (es) 2023-02-28
US20250368615A1 (en) 2025-12-04
WO2021260092A1 (en) 2021-12-30
TWI925847B (zh) 2026-05-21
US20240010631A1 (en) 2024-01-11
ZA202300924B (en) 2024-09-25
CN122059929A (zh) 2026-05-19
KR20230026450A (ko) 2023-02-24
CA3186996A1 (en) 2021-12-30
CO2023000186A2 (es) 2023-04-17
MX2022015435A (es) 2023-02-09
CN121873040A (zh) 2026-04-17

Similar Documents

Publication Publication Date Title
US12421208B2 (en) Chemical compounds
KR102929356B1 (ko) Parp1 억제제
JP2025503465A (ja) 脳腫瘍及び神経芽腫を処置する方法
EA048005B1 (ru) Производные хиноксалина в качестве противораковых лекарственных средств
HK40125769A (en) Parp1 inhibitors
HK40075454B (en) Parp1 inhibitors
HK40075454A (en) Parp1 inhibitors
EA048020B1 (ru) Ингибиторы parp1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251031

R150 Certificate of patent or registration of utility model

Ref document number: 7769650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150